シェーグレン症候群の世界市場2022年~2029年:種類別、用途別、流通チャネル別、地域別

◆英語タイトル:Global Sjogren’s Syndrome Market Size study & Forecast, by Type (Primary Sjogren's Syndrome and Secondary Sjogren's Syndrome), Application (Oral, Intravenous, and Subcutaneous), and Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies, and Others) and Regional Analysis, 2022-2029

Bizwit Research & Consultingが発行した調査報告書(BZW22DC044)◆商品コード:BZW22DC044
◆発行会社(リサーチ会社):Bizwit Research & Consulting
◆発行日:2022年10月17日
◆ページ数:約200
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥925,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

ビズウィットリサーチ社発行の本調査レポートによると、2021年におよそXX億ドルであった世界のシェーグレン症候群市場規模が、2022年から2029年の間にXX%以上成長すると予測されています。本レポートは、シェーグレン症候群の世界市場を対象とし、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析(新型コロナウイルス感染症の影響)、種類別分析(原発性シェーグレン症候群、二次性シェーグレン症候群)、用途別分析(経口、静脈内、皮下)、流通チャネル別分析(小売薬局、病院、オンライン薬局、その他)、地域別分析(北米、ヨーロッパ、アジア太平洋、中南米、その他地域)、競争分析、調査プロセスなど、多面的な分析結果をまとめたものです。なお、参入企業情報として、AbbVie Inc.、ADVANZ PHARMA Corp. Ltd、Biogen Inc、Bristol-Myers Squibb Co、Daiichi Sankyo Co. Ltd、Hikma Pharmaceuticals Plc、Johnson & Johnson、Novartis AG、Sanofi SA、Sun Pharmaceutical Industries Ltd.などが含まれております。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)

・世界のシェーグレン症候群市場規模:種類別
- 原発性シェーグレン症候群の市場規模
- 二次性シェーグレン症候群の市場規模

・世界のシェーグレン症候群市場規模:用途別
- 経口における市場規模
- 静脈内における市場規模
- 皮下における市場規模

・世界のシェーグレン症候群市場規模:流通チャネル別
- 小売薬局の市場規模
- 病院の市場規模
- オンライン薬局の市場規模
- その他流通チャネルの市場規模

・世界のシェーグレン症候群市場規模:地域別
- 北米のシェーグレン症候群市場規模
- ヨーロッパのシェーグレン症候群市場規模
- アジア太平洋のシェーグレン症候群市場規模
- 中南米のシェーグレン症候群市場規模
- その他地域のシェーグレン症候群市場規模

・競争分析
・調査プロセス

Global Sjogren’s Syndrome Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029.
Sjogren’s Syndrome also known as show grins is a type of autoimmune disease that affects different parts of the body that are responsible for producing fluids, like tears and spit (saliva). It mainly affects people aged between 40 to 60 years. Sjogren’s Syndrome symptoms include dry eyes & dry mouth. The increasing number of patients with Sjogren’s Syndrome and growing awareness towards Sjogren’s Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to Reston, Virginia, USA based Sjögren’s Foundation estimates – as of 2020, autoimmune diseases affect 5 to 8% of US residents. In addition, approximately four million American citizens are affected by Sjogren’s Syndrome, with more than 2.5 million patients are steel undiagnosed. Moreover, as per The National Institutes of Health (NIH) estimates – approximately 23.5 million Americans are affected by autoimmune diseases. Also, rising growth of pharmaceuticals sector in emerging markets and growing number of R&D activities in medical sector would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Sjogren’s Syndrome impedes the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sjogren’s Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factor such as presence of leading market players and availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising prevalence of Sjogren’s syndrome as well as growing healthcare infrastructure in the region.

Major market player included in this report are:
AbbVie Inc.
ADVANZ PHARMA Corp. Ltd
Biogen Inc
Bristol-Myers Squibb Co
Daiichi Sankyo Co. Ltd
Hikma Pharmaceuticals Plc
Johnson & Johnson
Novartis AG,
Sanofi SA
Sun Pharmaceutical Industries Ltd.

Recent Developments in the Market:
 In September 2022, Dublin Ireland based Horizon Therapeutics plc Announced Phase 2 trial of its new formulation Dazodalibep for the Treatment of Sjögren’s Syndrome. In addition, as per the score defined by the European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI), the drug has met the primary endpoint in patients with moderate-to-high systemic disease activity.

 In September 2022, Switzerland based pharma major Novartis announced completion of Phase II immune disorder trial of its new formulation named remibrutinib (LOU-064).

Global Sjogren’s Syndrome Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Application, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type
Primary Sjogren’s Syndrome
Secondary Sjogren’s Syndrome

By Application
Oral
Intravenous
Subcutaneous

By Distribution Channel
Retail Pharmacies
Hospitals
Online Pharmacies
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Sjogren’s Syndrome Market, by Region, 2019-2029 (USD Billion)
1.2.2. Sjogren’s Syndrome Market, by Type, 2019-2029 (USD Billion)
1.2.3. Sjogren’s Syndrome Market, by Application, 2019-2029 (USD Billion)
1.2.4. Sjogren’s Syndrome Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Sjogren’s Syndrome Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Sjogren’s Syndrome Market Dynamics
3.1. Sjogren’s Syndrome Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing number of patients with Sjogren’s Syndrome
3.1.1.2. Growing awareness towards Sjogren’s Syndrome.
3.1.1.3. Strategic initiatives from leading market players.
3.1.2. Market Challenges
3.1.2.1. High treatment cost associated with Sjogren’s Syndrome
3.1.3. Market Opportunities
3.1.3.1. Rising growth of pharmaceuticals sector in emerging markets.
3.1.3.2. Growing number of R&D activities in medical sector.
Chapter 4. Global Sjogren’s Syndrome Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Sjogren’s Syndrome Market, by Type
6.1. Market Snapshot
6.2. Global Sjogren’s Syndrome Market by Type, Performance – Potential Analysis
6.3. Global Sjogren’s Syndrome Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Sjogren’s Syndrome Market, Sub Segment Analysis
6.4.1. Primary Sjogren’s Syndrome
6.4.2. Secondary Sjogren’s Syndrome
Chapter 7. Global Sjogren’s Syndrome Market, by Application
7.1. Market Snapshot
7.2. Global Sjogren’s Syndrome Market by Application, Performance – Potential Analysis
7.3. Global Sjogren’s Syndrome Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
7.4. Sjogren’s Syndrome Market, Sub Segment Analysis
7.4.1. Oral
7.4.2. Intravenous
7.4.3. Subcutaneous
Chapter 8. Global Sjogren’s Syndrome Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Sjogren’s Syndrome Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Sjogren’s Syndrome Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Sjogren’s Syndrome Market, Sub Segment Analysis
8.4.1. Retail Pharmacies
8.4.2. Hospitals
8.4.3. Online Pharmacies
8.4.4. Others
Chapter 9. Global Sjogren’s Syndrome Market, Regional Analysis
9.1. Sjogren’s Syndrome Market, Regional Market Snapshot
9.2. North America Sjogren’s Syndrome Market
9.2.1. U.S. Sjogren’s Syndrome Market
9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Sjogren’s Syndrome Market
9.3. Europe Sjogren’s Syndrome Market Snapshot
9.3.1. U.K. Sjogren’s Syndrome Market
9.3.2. Germany Sjogren’s Syndrome Market
9.3.3. France Sjogren’s Syndrome Market
9.3.4. Spain Sjogren’s Syndrome Market
9.3.5. Italy Sjogren’s Syndrome Market
9.3.6. Rest of Europe Sjogren’s Syndrome Market
9.4. Asia-Pacific Sjogren’s Syndrome Market Snapshot
9.4.1. China Sjogren’s Syndrome Market
9.4.2. India Sjogren’s Syndrome Market
9.4.3. Japan Sjogren’s Syndrome Market
9.4.4. Australia Sjogren’s Syndrome Market
9.4.5. South Korea Sjogren’s Syndrome Market
9.4.6. Rest of Asia Pacific Sjogren’s Syndrome Market
9.5. Latin America Sjogren’s Syndrome Market Snapshot
9.5.1. Brazil Sjogren’s Syndrome Market
9.5.2. Mexico Sjogren’s Syndrome Market
9.6. Rest of The World Sjogren’s Syndrome Market

Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. AbbVie Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. ADVANZ PHARMA Corp. Ltd
10.2.3. Biogen Inc
10.2.4. Bristol-Myers Squibb Co
10.2.5. Daiichi Sankyo Co. Ltd
10.2.6. Hikma Pharmaceuticals Plc
10.2.7. Johnson & Johnson
10.2.8. Novartis AG
10.2.9. Sanofi SA
10.2.10. Sun Pharmaceutical Industries Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ シェーグレン症候群の世界市場2022年~2029年:種類別、用途別、流通チャネル別、地域別(Global Sjogren’s Syndrome Market Size study & Forecast, by Type (Primary Sjogren's Syndrome and Secondary Sjogren's Syndrome), Application (Oral, Intravenous, and Subcutaneous), and Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies, and Others) and Regional Analysis, 2022-2029)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆